These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12206796)

  • 1. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part III. Ethical considerations.
    Fardeau M
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S52-4. PubMed ID: 12206796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale.
    Thioudellet C; Blot S; Squiban P; Fardeau M; Braun S
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S49-51. PubMed ID: 12206795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol.
    Romero NB; Benveniste O; Payan C; Braun S; Squiban P; Herson S; Fardeau M
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S45-8. PubMed ID: 12206794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
    Duan D
    Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy.
    Romero NB; Braun S; Benveniste O; Leturcq F; Hogrel JY; Morris GE; Barois A; Eymard B; Payan C; Ortega V; Boch AL; Lejean L; Thioudellet C; Mourot B; Escot C; Choquel A; Recan D; Kaplan JC; Dickson G; Klatzmann D; Molinier-Frenckel V; Guillet JG; Squiban P; Herson S; Fardeau M
    Hum Gene Ther; 2004 Nov; 15(11):1065-76. PubMed ID: 15610607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [About a phase I gene therapy clinical trial with a full-length dystrophin gene-plasmid in Duchenne/Becker muscular dystrophy].
    Fardeau M; Braun S; Romero NB; Hogrel JY; Rouche A; Ortega V; Mourot B; Squiban P; Benveniste O; Herson S
    J Soc Biol; 2005; 199(1):29-32. PubMed ID: 16114261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duchenne muscular dystrophy: current knowledge, treatment, and future prospects.
    Biggar WD; Klamut HJ; Demacio PC; Stevens DJ; Ray PN
    Clin Orthop Relat Res; 2002 Aug; (401):88-106. PubMed ID: 12151886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic integration of the full-length dystrophin coding sequence in Duchenne muscular dystrophy induced pluripotent stem cells.
    Farruggio AP; Bhakta MS; du Bois H; Ma J; P Calos M
    Biotechnol J; 2017 Apr; 12(4):. PubMed ID: 28139886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy.
    Zhang G; Ludtke JJ; Thioudellet C; Kleinpeter P; Antoniou M; Herweijer H; Braun S; Wolff JA
    Hum Gene Ther; 2004 Aug; 15(8):770-82. PubMed ID: 15319034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies for Duchenne and Becker dystrophies.
    Voisin V; de la Porte S
    Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.
    Seto JT; Ramos JN; Muir L; Chamberlain JS; Odom GL
    Curr Gene Ther; 2012 Jun; 12(3):139-51. PubMed ID: 22533379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
    Duan D
    Mol Ther; 2018 Oct; 26(10):2337-2356. PubMed ID: 30093306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duchenne and Becker muscular dystrophies.
    Flanigan KM
    Neurol Clin; 2014 Aug; 32(3):671-88, viii. PubMed ID: 25037084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD?
    Wells DJ; Wells KE
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S11-22. PubMed ID: 12206790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies.
    Le Rumeur E
    Bosn J Basic Med Sci; 2015 Jul; 15(3):14-20. PubMed ID: 26295289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligonucleotide-mediated gene therapy for muscular dystrophies.
    Rando TA
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S55-60. PubMed ID: 12206797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
    Matsuo M
    IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.